| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
DP2 <100 nM (Ki)
Pexopiprant specifically targets the prostaglandin D2 receptor 2 (DP2/CRTH2). DP2 is a G-protein coupled receptor that mediates the chemotaxis of Th2 cells, eosinophils, and basophils. By binding to this receptor, Pexopiprant blocks the downstream inflammatory signaling typically triggered by its endogenous ligand, Prostaglandin D2 (PGD2). |
|---|---|
| ln Vitro |
Pexopiprant is a potent antagonist of the DP2 receptor, exhibiting an inhibitory constant Ki value of less than 100 nM. It demonstrates high selectivity for DP2 over other prostanoid receptors. In functional assays, it effectively inhibits PGD2-induced cell migration and activation of Th2 cells and eosinophils.
|
| ln Vivo |
While specific in vivo data for Pexopiprant is limited, it is classified as an oral antagonist for asthma research. In standard animal models of asthma (e.g., ovalbumin or house dust mite-induced airway inflammation in mice), DP2 antagonists typically demonstrate efficacy in reducing airway hyperresponsiveness, eosinophil infiltration into the lungs, and levels of Th2 cytokines.
|
| Enzyme Assay |
The specific protocol for DP2 receptor binding would involve competitive radioligand binding assays. HEK-293 cells expressing the human recombinant DP2 receptor are lysed to obtain membrane fractions. These membranes are then incubated with [3H]-PGD2 (the radioligand) and varying concentrations of Pexopiprant (e.g., 0.1 nM to 10 uM). After a 60-minute incubation at room temperature, bound and free ligands are separated by filtration through GF/B filters. The radioactivity is measured using a scintillation counter, and Ki values are calculated via Cheng-Prusoff equation.
|
| Cell Assay |
To assess Pexopiprant's functional antagonism, a chemotaxis assay is commonly used. Primary human eosinophils or Th2 cell lines are isolated and placed in the upper chamber of a 96-well chemotaxis plate. Various concentrations of Pexopiprant (0.1-1,000 nM) are added to the cells, and PGD2 is placed in the lower chamber as the chemoattractant. After a 2-4 hour incubation, cells that migrated to the lower chamber are quantified using a fluorescent dye or by ATP quantification (CellTiter-Glo).
|
| Animal Protocol |
A standard in vivo protocol for evaluating DP2 antagonists uses an ovalbumin (OVA)-induced asthma mouse model. Female BALB/c mice are sensitized with OVA/alum and then challenged intranasally with OVA. Pexopiprant is administered orally at doses ranging from 1-30 mg/kg, typically once or twice daily. Bronchoalveolar lavage fluid (BALF) is collected to count eosinophils. Lung tissues are harvested for histology (H&E staining) and for measuring Th2 cytokines (IL-4, IL-5, IL-13) by ELISA.
|
| ADME/Pharmacokinetics |
As a small molecule DP2 antagonist designed for oral administration, Pexopiprant is expected to have favorable oral bioavailability. While the specific half-life and Cmax for this compound are not widely published, the chemical class generally possesses good metabolic stability, with clearance primarily mediated by hepatic cytochrome P450 enzymes and excretion via the biliary/fecal route.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Pexopiprant has not been published in standard databases. However, as an oral small molecule, standard preclinical safety evaluation would include acute and repeat-dose toxicity studies in rodents and non-rodents to identify any target organ toxicity. Based on the mechanism, possible adverse events may relate to interference with immune function. No specific genotoxicity or carcinogenicity data is available.
|
| References | |
| Additional Infomation |
Pexopiprant is a small molecule drug. The monoisotope molecular weight of piperopirant is 455.05 Da.
Pexopiprant is a research tool for studying DP2 pharmacology. It has not yet received regulatory approval for clinical use. Due to the mechanism of the DP2 receptor in allergic inflammation, this class of agents has been widely researched for asthma, allergic rhinitis, and atopic dermatitis. Pexopiprant acts as an antagonist, blocking the CRTH2 receptor to reduce PGD2-mediated eosinophil migration and activation. |
| Molecular Formula |
C21H17CL2F2NO4
|
|---|---|
| Molecular Weight |
456.27
|
| Exact Mass |
455.05
|
| CAS # |
932708-14-0
|
| PubChem CID |
16038335
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
539.5±45.0 °C at 760 mmHg
|
| Flash Point |
280.1±28.7 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
6.04
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
565
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC1=NC2=C(C=CC(=C2C(=C1CC3=CC=C(C=C3)Cl)OC(F)F)OCC(=O)O)Cl
|
| InChi Key |
LZLJEKKWOIJMSR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H17Cl2F2NO4/c1-2-15-13(9-11-3-5-12(22)6-4-11)20(30-21(24)25)18-16(29-10-17(27)28)8-7-14(23)19(18)26-15/h3-8,21H,2,9-10H2,1H3,(H,27,28)
|
| Chemical Name |
2-[8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethylquinolin-5-yl]oxyacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (219.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1917 mL | 10.9584 mL | 21.9168 mL | |
| 5 mM | 0.4383 mL | 2.1917 mL | 4.3834 mL | |
| 10 mM | 0.2192 mL | 1.0958 mL | 2.1917 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
